Clinical Trial

The Antiemetic Effects of Increased Splanchnic Perfusion, Induced by the Gut Hormone GIP, in Healthy Individuals

Study acronym: GIP EMESIS
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This study investigates whether the gut hormone glucose-dependent insulinotropic polypeptide (GIP) can reduce feelings of nausea. GIP is naturally released after meals and is administered intravenously to healthy participants during the experiment. Nausea is induced using either glucagon-like peptide 1 (GLP-1), another gut hormone, or apomorphine, a medication known to trigger nausea. By combining these substances, the study aims to determine whether GIP can alleviate nausea. The findings may improve understanding of interactions between the gut and the brain.
Trial Details
NCT Number NCT07687589
Lead Sponsor University of Copenhagen
Conditions Emesis
Enrollment 14 participants
Start Date 2026-05-19
Primary Completion 2026-11-30 (estimated)
Study Completion 2027-04-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-07